Please login to the form below

Not currently logged in
Email:
Password:

Accenture and BMS launch Indian pharmacovigilance centre

Accenture and Bristol-Myers Squibb (BMS) have launched a center for pharmacovigilance in Chennai, India.

Accenture and Bristol-Myers Squibb (BMS) have launched a center for pharmacovigilance in Chennai, India.

The new centre will process and code of adverse event data and generate regulatory periodic and aggregate reports on safety, as well as physician medical review of adverse events. Over 140 Accenture employees will run the site.

Pharmacovigilance involves monitoring safety data, assessment and reporting of potential side effects of approved medicines.

According to Accenture and BMS, the jv is the first of its kind involving a collaboration for 'end-to-end' safety case processing.

The team is organised as a parallel process and extension of the BMS pharmacovigilance headquarters' operations, which will handle data and reports between the two companies.

Part of a multi-year R&D agreement signed in April 2007, the jv will aid BMS's in its efforts to expand R&D operations in India as part of the company's global strategy.

Dr John Balian, senior vice-president of global pharmacovigilance and epidemiology at BMS, said: "Working with Accenture, we will continue to access world-class talent to deliver on our regulatory obligations, while enhancing our focus on patient safety."

Eric Sandor, managing director of Accenture Pharmacovigilance Services, added: "Through a truly collaborative partnership with BMS, we have established an industry leading operation that is delivering substantial efficiency and improved flexibility for the company's pharmacovigilance organisation."

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics